Previous close | 6.60 |
Open | 6.60 |
Bid | 0.00 x 3519200 |
Ask | 0.00 x 165200 |
Day's range | 6.60 - 6.60 |
52-week range | 6.45 - 14.94 |
Volume | |
Avg. volume | 0 |
Market cap | 15.071M |
Beta (5Y monthly) | 1.10 |
PE ratio (TTM) | N/A |
EPS (TTM) | -547.50 |
Earnings date | 28 Aug 2023 - 01 Sept 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 18.84 |
N=1,172 Australian pain patientsDatapoints collected from commencing NanaBis™ (baseline) up to month 1255% improvement in pain relief75% of patients reduced their opioid use31% Improvements in Quality of Life as it relates to pain interference92% of patients with bone metastasis from cancer had reduced their pain severity and pain interference (Quality of Life) scores at 6-monthsNew “ENHANCE” study expects to onboard March 2023 Sydney, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Medlab Clinical Ltd (ASX:M
Medlab Clinical ( ASX:MDC ) Full Year 2022 Results Key Financial Results Revenue: AU$1.54m (up 110% from FY 2021). Net...
Every investor in Medlab Clinical Limited ( ASX:MDC ) should be aware of the most powerful shareholder groups. Large...